AKBA Q1 2023 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M-35.2% YoY

Gross Profit

$20M49.5% margin

Operating Income

-$26M-64.0% margin

Net Income

-$27M-67.2% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-27.5%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$277M

Total Liabilities

$291M

Stockholders' Equity

-$14M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$62M	-35.2%
Gross Profit	$20M	$30M	-34.7%
Operating Income	-$26M	-$58M	+56.2%
Net Income	-$27M	-$62M	+56.9%

Revenue Segments

Product

$35M87%

License Collaboration And Other Revenue

$5M13%